Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-04-26

AUTHORS

Xiang Yan, Chen Feng, Ying Lou, Zhiguang Zhou

ABSTRACT

IntroductionLY2963016 insulin glargine (LY IGlar), a biosimilar of Lantus® insulin glargine (IGlar), demonstrated comparable efficacy and safety versus the reference product in Chinese patients with type 1 diabetes mellitus (T1DM) in the randomized, phase III ABES trial. This post hoc analysis aimed to provide the first evidence for switching from IGlar to LY IGlar in Chinese patients with T1DM.MethodsThis analysis included 210/272 patients with T1DM (77.2%) from the ABES trial who were receiving IGlar at screening. We compared antihyperglycemic efficacy, safety, and immunogenicity in patients randomized to LY IGlar (n = 104) versus those who continued to receive IGlar (n = 106).ResultsThere was no significant difference between groups in least-squares mean (LSMean) change in HbA1c from baseline to 24 weeks (LY IGlar − 0.10%, IGlar − 0.08%; LSMean difference [95% confidence interval] − 0.02% [− 0.24, 0.19]). At 24 weeks (last observation carried forward), a similar proportion of patients in each group achieved glycated hemoglobin less than 7.0% (LY IGlar 26.5%, IGlar 32.1%; P = 0.447) and 6.5% or less (LY IGlar 16.7%, IGlar 20.8%; P = 0.482). There were no significant differences between groups in LSMean of self-monitored blood glucose values, or total or basal insulin dose at 24 weeks. Patients in the LY IGlar and IGlar groups had a similar incidence of total hypoglycemia (blood glucose level 70 mg/dL or less, 91.4% vs. 92.5%) and treatment-emergent adverse events (AEs; 75.0% vs. 67.0%), and a low and similar incidence of serious AEs, injection site AEs, and allergic AEs. Similar proportions of patients in the LY IGlar and IGlar groups had treatment-emergent antibody responses (LY IGlar 27.2%, IGlar 28.3%) and detectable insulin antibodies (LY IGlar 52.4%, IGlar 53.8%).ConclusionIn Chinese patients with T1DM previously treated with IGlar, switching to LY IGlar for 24 weeks resulted in similar efficacy and safety outcomes as remaining on IGlar therapy.Clinical Trial RegistrationNCT03338023. More... »

PAGES

1161-1174

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01262-8

DOI

http://dx.doi.org/10.1007/s13300-022-01262-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147380566

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35471721


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Zhong Road, 410011, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452708.c", 
          "name": [
            "National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Zhong Road, 410011, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yan", 
        "givenName": "Xiang", 
        "id": "sg:person.01127310032.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127310032.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lilly (Shanghai) Management Co., Ltd., No. 288 Shimen No.1 Road, Jingan District, 200041, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Lilly (Shanghai) Management Co., Ltd., No. 288 Shimen No.1 Road, Jingan District, 200041, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feng", 
        "givenName": "Chen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lilly Suzhou Pharmaceutical Co., Ltd., No. 288 Shimen No.1 Road, Jingan District, 200041, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Lilly Suzhou Pharmaceutical Co., Ltd., No. 288 Shimen No.1 Road, Jingan District, 200041, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lou", 
        "givenName": "Ying", 
        "id": "sg:person.013464400241.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013464400241.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Zhong Road, 410011, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452708.c", 
          "name": [
            "National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Zhong Road, 410011, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhou", 
        "givenName": "Zhiguang", 
        "id": "sg:person.012164724157.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012164724157.16"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1208/s12248-012-9408-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038538434", 
          "https://doi.org/10.1208/s12248-012-9408-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-017-0218-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050557", 
          "https://doi.org/10.1007/s40259-017-0218-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-018-0549-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111058760", 
          "https://doi.org/10.1007/s13300-018-0549-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-018-0259-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100589854", 
          "https://doi.org/10.1007/s40259-018-0259-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-04-26", 
    "datePublishedReg": "2022-04-26", 
    "description": "IntroductionLY2963016 insulin glargine (LY\u00a0IGlar), a biosimilar of Lantus\u00ae insulin glargine (IGlar), demonstrated comparable efficacy and safety versus the reference product in Chinese patients with type\u00a01 diabetes mellitus (T1DM) in the randomized, phase\u00a0III ABES trial. This post hoc analysis aimed to provide the first evidence for switching from IGlar to LY\u00a0IGlar in Chinese patients with T1DM.MethodsThis analysis included 210/272 patients with T1DM (77.2%) from the ABES trial who were receiving IGlar at screening. We compared antihyperglycemic efficacy, safety, and immunogenicity in patients randomized to LY\u00a0IGlar (n\u2009=\u2009104) versus those who continued to receive IGlar (n\u2009=\u2009106).ResultsThere was no significant difference between groups in least-squares mean (LSMean) change in HbA1c from baseline to 24\u00a0weeks (LY\u00a0IGlar \u2212\u20090.10%, IGlar \u2212\u20090.08%; LSMean difference [95% confidence interval] \u2212\u20090.02% [\u2212\u20090.24, 0.19]). At 24\u00a0weeks (last observation carried forward), a similar proportion of patients in each group achieved glycated hemoglobin less than 7.0% (LY\u00a0IGlar 26.5%, IGlar 32.1%; P\u2009=\u20090.447) and 6.5% or less (LY\u00a0IGlar 16.7%, IGlar 20.8%; P\u2009=\u20090.482). There were no significant differences between groups in LSMean of self-monitored blood glucose values, or total or basal insulin dose at 24\u00a0weeks. Patients in the LY\u00a0IGlar and IGlar groups had a similar incidence of total hypoglycemia (blood glucose level 70\u00a0mg/dL or less, 91.4% vs. 92.5%) and treatment-emergent adverse events (AEs; 75.0% vs. 67.0%), and a low and similar incidence of serious AEs, injection site AEs, and allergic AEs. Similar proportions of patients in the LY\u00a0IGlar and IGlar groups had treatment-emergent antibody responses (LY\u00a0IGlar 27.2%, IGlar 28.3%) and detectable insulin antibodies (LY\u00a0IGlar 52.4%, IGlar 53.8%).ConclusionIn Chinese patients with T1DM previously treated with IGlar, switching to LY\u00a0IGlar for 24\u00a0weeks resulted in similar efficacy and safety outcomes as remaining on IGlar therapy.Clinical Trial RegistrationNCT03338023.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01262-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "insulin glargine", 
      "Chinese patients", 
      "IGlar group", 
      "similar incidence", 
      "treatment-emergent adverse events", 
      "detectable insulin antibodies", 
      "LY2963016 insulin glargine", 
      "basal insulin dose", 
      "phase 3 trial", 
      "similar proportions", 
      "blood glucose values", 
      "significant differences", 
      "Post Hoc Analysis", 
      "total hypoglycemia", 
      "serious AEs", 
      "open label", 
      "self-monitored blood glucose values", 
      "adverse events", 
      "diabetes mellitus", 
      "insulin dose", 
      "antibody response", 
      "comparable efficacy", 
      "MethodsThis analysis", 
      "insulin antibodies", 
      "similar efficacy", 
      "IGlar", 
      "Hoc Analysis", 
      "safety outcomes", 
      "patients", 
      "glargine", 
      "glucose values", 
      "antihyperglycemic efficacy", 
      "type 1", 
      "T1DM", 
      "weeks", 
      "efficacy", 
      "trials", 
      "incidence", 
      "reference product", 
      "first evidence", 
      "group", 
      "safety", 
      "mellitus", 
      "Randomized", 
      "hypoglycemia", 
      "ResultsThere", 
      "therapy", 
      "immunogenicity", 
      "Lantus", 
      "proportion", 
      "dose", 
      "baseline", 
      "antibodies", 
      "hemoglobin", 
      "outcomes", 
      "differences", 
      "biosimilars", 
      "Ae", 
      "Lys", 
      "response", 
      "evidence", 
      "LSmeans", 
      "analysis", 
      "events", 
      "post", 
      "changes", 
      "types", 
      "values", 
      "products", 
      "phase"
    ], 
    "name": "Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus\u00ae): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial", 
    "pagination": "1161-1174", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147380566"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01262-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35471721"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01262-8", 
      "https://app.dimensions.ai/details/publication/pub.1147380566"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_945.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01262-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01262-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01262-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01262-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01262-8'


 

This table displays all metadata directly associated to this object as RDF triples.

172 TRIPLES      21 PREDICATES      99 URIs      87 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01262-8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N1390a88a2be0485fb87a12024254e842
4 schema:citation sg:pub.10.1007/s13300-018-0549-3
5 sg:pub.10.1007/s40259-017-0218-5
6 sg:pub.10.1007/s40259-018-0259-4
7 sg:pub.10.1208/s12248-012-9408-8
8 schema:datePublished 2022-04-26
9 schema:datePublishedReg 2022-04-26
10 schema:description IntroductionLY2963016 insulin glargine (LY IGlar), a biosimilar of Lantus® insulin glargine (IGlar), demonstrated comparable efficacy and safety versus the reference product in Chinese patients with type 1 diabetes mellitus (T1DM) in the randomized, phase III ABES trial. This post hoc analysis aimed to provide the first evidence for switching from IGlar to LY IGlar in Chinese patients with T1DM.MethodsThis analysis included 210/272 patients with T1DM (77.2%) from the ABES trial who were receiving IGlar at screening. We compared antihyperglycemic efficacy, safety, and immunogenicity in patients randomized to LY IGlar (n = 104) versus those who continued to receive IGlar (n = 106).ResultsThere was no significant difference between groups in least-squares mean (LSMean) change in HbA1c from baseline to 24 weeks (LY IGlar − 0.10%, IGlar − 0.08%; LSMean difference [95% confidence interval] − 0.02% [− 0.24, 0.19]). At 24 weeks (last observation carried forward), a similar proportion of patients in each group achieved glycated hemoglobin less than 7.0% (LY IGlar 26.5%, IGlar 32.1%; P = 0.447) and 6.5% or less (LY IGlar 16.7%, IGlar 20.8%; P = 0.482). There were no significant differences between groups in LSMean of self-monitored blood glucose values, or total or basal insulin dose at 24 weeks. Patients in the LY IGlar and IGlar groups had a similar incidence of total hypoglycemia (blood glucose level 70 mg/dL or less, 91.4% vs. 92.5%) and treatment-emergent adverse events (AEs; 75.0% vs. 67.0%), and a low and similar incidence of serious AEs, injection site AEs, and allergic AEs. Similar proportions of patients in the LY IGlar and IGlar groups had treatment-emergent antibody responses (LY IGlar 27.2%, IGlar 28.3%) and detectable insulin antibodies (LY IGlar 52.4%, IGlar 53.8%).ConclusionIn Chinese patients with T1DM previously treated with IGlar, switching to LY IGlar for 24 weeks resulted in similar efficacy and safety outcomes as remaining on IGlar therapy.Clinical Trial RegistrationNCT03338023.
11 schema:genre article
12 schema:isAccessibleForFree true
13 schema:isPartOf N384d03680936480f9d5c9513c8753694
14 Naf46ef1a11cf49d0bbe8c51375c46b84
15 sg:journal.1044057
16 schema:keywords Ae
17 Chinese patients
18 Hoc Analysis
19 IGlar
20 IGlar group
21 LSmeans
22 LY2963016 insulin glargine
23 Lantus
24 Lys
25 MethodsThis analysis
26 Post Hoc Analysis
27 Randomized
28 ResultsThere
29 T1DM
30 adverse events
31 analysis
32 antibodies
33 antibody response
34 antihyperglycemic efficacy
35 basal insulin dose
36 baseline
37 biosimilars
38 blood glucose values
39 changes
40 comparable efficacy
41 detectable insulin antibodies
42 diabetes mellitus
43 differences
44 dose
45 efficacy
46 events
47 evidence
48 first evidence
49 glargine
50 glucose values
51 group
52 hemoglobin
53 hypoglycemia
54 immunogenicity
55 incidence
56 insulin antibodies
57 insulin dose
58 insulin glargine
59 mellitus
60 open label
61 outcomes
62 patients
63 phase
64 phase 3 trial
65 post
66 products
67 proportion
68 reference product
69 response
70 safety
71 safety outcomes
72 self-monitored blood glucose values
73 serious AEs
74 significant differences
75 similar efficacy
76 similar incidence
77 similar proportions
78 therapy
79 total hypoglycemia
80 treatment-emergent adverse events
81 trials
82 type 1
83 types
84 values
85 weeks
86 schema:name Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
87 schema:pagination 1161-1174
88 schema:productId N25dbe3faac9f4449aa94fb47942a106f
89 N99eddfbb585347c2b2692d22fb4bdcfc
90 Ne22dde34c13d4e74a36a6a65f6b3d8ae
91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147380566
92 https://doi.org/10.1007/s13300-022-01262-8
93 schema:sdDatePublished 2022-08-04T17:13
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher N3a57b3b0c7e7477ea4b963888d811c3f
96 schema:url https://doi.org/10.1007/s13300-022-01262-8
97 sgo:license sg:explorer/license/
98 sgo:sdDataset articles
99 rdf:type schema:ScholarlyArticle
100 N1390a88a2be0485fb87a12024254e842 rdf:first sg:person.01127310032.27
101 rdf:rest Nffa45394d8d643bfafe8c9fc36347dba
102 N22464eca5c114d7ca047add6b39cf37d rdf:first sg:person.013464400241.17
103 rdf:rest N3c944ce7ec59441b9419f476571f8c3d
104 N25dbe3faac9f4449aa94fb47942a106f schema:name pubmed_id
105 schema:value 35471721
106 rdf:type schema:PropertyValue
107 N384d03680936480f9d5c9513c8753694 schema:issueNumber 6
108 rdf:type schema:PublicationIssue
109 N3a57b3b0c7e7477ea4b963888d811c3f schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 N3c944ce7ec59441b9419f476571f8c3d rdf:first sg:person.012164724157.16
112 rdf:rest rdf:nil
113 N83897600ef764eee8dea984213ca2115 schema:affiliation grid-institutes:None
114 schema:familyName Feng
115 schema:givenName Chen
116 rdf:type schema:Person
117 N99eddfbb585347c2b2692d22fb4bdcfc schema:name dimensions_id
118 schema:value pub.1147380566
119 rdf:type schema:PropertyValue
120 Naf46ef1a11cf49d0bbe8c51375c46b84 schema:volumeNumber 13
121 rdf:type schema:PublicationVolume
122 Ne22dde34c13d4e74a36a6a65f6b3d8ae schema:name doi
123 schema:value 10.1007/s13300-022-01262-8
124 rdf:type schema:PropertyValue
125 Nffa45394d8d643bfafe8c9fc36347dba rdf:first N83897600ef764eee8dea984213ca2115
126 rdf:rest N22464eca5c114d7ca047add6b39cf37d
127 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
128 schema:name Medical and Health Sciences
129 rdf:type schema:DefinedTerm
130 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
131 schema:name Clinical Sciences
132 rdf:type schema:DefinedTerm
133 sg:journal.1044057 schema:issn 1869-6953
134 1869-6961
135 schema:name Diabetes Therapy
136 schema:publisher Springer Nature
137 rdf:type schema:Periodical
138 sg:person.01127310032.27 schema:affiliation grid-institutes:grid.452708.c
139 schema:familyName Yan
140 schema:givenName Xiang
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127310032.27
142 rdf:type schema:Person
143 sg:person.012164724157.16 schema:affiliation grid-institutes:grid.452708.c
144 schema:familyName Zhou
145 schema:givenName Zhiguang
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012164724157.16
147 rdf:type schema:Person
148 sg:person.013464400241.17 schema:affiliation grid-institutes:None
149 schema:familyName Lou
150 schema:givenName Ying
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013464400241.17
152 rdf:type schema:Person
153 sg:pub.10.1007/s13300-018-0549-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111058760
154 https://doi.org/10.1007/s13300-018-0549-3
155 rdf:type schema:CreativeWork
156 sg:pub.10.1007/s40259-017-0218-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085050557
157 https://doi.org/10.1007/s40259-017-0218-5
158 rdf:type schema:CreativeWork
159 sg:pub.10.1007/s40259-018-0259-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100589854
160 https://doi.org/10.1007/s40259-018-0259-4
161 rdf:type schema:CreativeWork
162 sg:pub.10.1208/s12248-012-9408-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038538434
163 https://doi.org/10.1208/s12248-012-9408-8
164 rdf:type schema:CreativeWork
165 grid-institutes:None schema:alternateName Lilly (Shanghai) Management Co., Ltd., No. 288 Shimen No.1 Road, Jingan District, 200041, Shanghai, China
166 Lilly Suzhou Pharmaceutical Co., Ltd., No. 288 Shimen No.1 Road, Jingan District, 200041, Shanghai, China
167 schema:name Lilly (Shanghai) Management Co., Ltd., No. 288 Shimen No.1 Road, Jingan District, 200041, Shanghai, China
168 Lilly Suzhou Pharmaceutical Co., Ltd., No. 288 Shimen No.1 Road, Jingan District, 200041, Shanghai, China
169 rdf:type schema:Organization
170 grid-institutes:grid.452708.c schema:alternateName National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Zhong Road, 410011, Changsha, Hunan, China
171 schema:name National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Zhong Road, 410011, Changsha, Hunan, China
172 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...